Highlights Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-01 pm EDT			5-day change	1st Jan Change
1.86 ^USD	+5.08%		+0.81%	+6.90%

Mar. 11	Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	MT
Mar. 11	Top Premarket Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	Mar. 11	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 14	CI
Reverse Split: 1 of 22	23-08-31	FA
Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US	23-08-16	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab	23-06-20	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-10	CI
Sonnet Biotherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 At the 2023 American Association for Cancer Research Annual Meeting	23-04-18	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-13	CI
Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates	23-02-01	CI
Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010	23-01-19	CI
Sonnet BioTherapeutics Holdings, Inc. Announces A Collaboration with Roche for the Clinical Evaluation of SON-1010 with Atezolizumab in Ovarian Cancer	23-01-09	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-15	CI
Sonnet BioTherapeutics Holdings, Inc. Announces Interim Data in Two Phase 1 Dose-Escalation Trials of Son-1010	22-11-02	CI
Sonnet BioTherapeutics Signs Collaboration Agreement With Janssen Biotech	22-10-31	MT
Sonnet BioTherapeutics Holdings, Inc. Announces Collaboration Agreement with Janssen Biotech, Inc	22-10-31	CI
Sonnet BioTherapeutics Regains Compliance With Nasdaq's Minimum Bid Price Rule	22-10-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Highlights

Filters